GLP-1s, Anesthesia, and Surgery Day: The Full-Stomach Problem, Solved by Planning

A drug that holds food in your stomach longer meets a medical ritual built on the promise of an empty one: that collision — GLP-1 therapy and anesthesia — produced case reports, ultrasound studies, dueling society guidelines, and a great deal of patient confusion between 2023 and today. The practical stakes are simple: millions of people on these medications will have surgery, endoscopy, or sedation this year, and the difference between a smooth morning and a cancelled (or genuinely dangerous) one is mostly communication and a few days of planning. Here is the physiology, the evolution of the guidance, and the checklist that makes you the easiest case on the day's schedule.

Why anesthesiologists care about your stomach

General anesthesia and deep sedation switch off the airway's protective reflexes. If the stomach holds food or liquid, that content can travel up and be inhaled — pulmonary aspiration — a rare but serious complication that fasting rules exist to prevent: the familiar "nothing after midnight" is aspiration prophylaxis, engineered around normal gastric emptying times. GLP-1 agonists intervene precisely there: slowed gastric emptying is a core mechanism, strongest in the early months and after dose increases, variable between individuals, and — this is the operational problem — poorly predicted by feeling. A patient can be comfortably "empty" by sensation and standard fasting clock while gastric ultrasound shows a full stomach. That mismatch is what filled the case literature: reports of regurgitation and aspiration in fasted GLP-1 users, followed by imaging studies finding retained gastric contents in a strikingly higher share of medicated patients than controls — figures like roughly half versus a fifth in some cohorts — despite identical fasting.

The guidance, and how it matured

The first institutional answer came fast and blunt: 2023 anesthesiology guidance suggested holding GLP-1s before elective procedures — the day of surgery for daily formulations, a week prior for weekly ones — a defensible first draft written amid uncertainty. Experience and data then complicated it. A week's hold barely dents drug levels for molecules with five-to-seven-day half-lives; skipping doses destabilizes diabetes control in the patients who need stability most; withdrawal-and-restart cycles invite the side-effect reset of re-titration; and accumulating studies suggested that a clear-liquid-only diet for roughly 24 hours before the procedure empties even a slowed stomach far more reliably than dose arithmetic. So the multi-society clinical guidance that followed in 2024–2025 — anesthesiology together with the GI and surgical societies — shifted to individualized management: most patients continue their medication, adopt a 24-hour clear-liquid protocol before the procedure, and get screened for elevated-risk features (active GI symptoms like nausea or early fullness, recent dose escalation, other emptying-slowing conditions); point-of-care gastric ultrasound stands ready to adjudicate uncertain cases on the table's edge, and full-stomach precautions — rapid-sequence induction, or rescheduling — handle the residual risk. Institutions vary in how fully they've adopted the newer framework, which is one more reason the conversation below matters more than any summary, including this one.

Your checklist, in chronological order

From the moment a procedure is scheduled, the sequence runs like this. Disclose immediately and everywhere: tell the surgeon's scheduler, the pre-anesthesia clinic, and the endoscopist that you take semaglutide or tirzepatide, the dose, the day of your weekly injection, and how recently the dose changed — put it in the intake forms and say it out loud; compounded users, disclose that too, including concentration, since dosing ambiguity is itself a risk factor worth naming. Ask the specific question: "what is your GLP-1 protocol — do I continue or hold, and what's my liquid-diet window?" and get the answer attached to your actual procedure date and injection schedule; if told to hold a weekly drug, ask whether shifting the injection day beats skipping it. Execute the diet exactly: if given the 24-hour clear-liquid instruction, "clear" means water, clear broth, pulp-free juice, black coffee or tea — not milk, not smoothies, not soup with bits — and the standard pre-op fasting cutoffs still apply on top. Flag symptoms honestly on the day: nausea, vomiting, reflux, or unusual fullness that morning are exactly what the team must know before induction — a rescheduled case is an inconvenience; an aspiration is an emergency. Diabetics coordinate the parallel plan: any held GLP-1 doses interact with insulin and other agents, so glucose management across the fast is its own explicit conversation. And afterward, restart per instructions — typically once you're eating normally — asking whether any held weekly dose resets your titration.

Special rooms, same physics

Three settings deserve their own line. Endoscopy sits at the center of this issue twice over — sedation plus a camera in the very organ in question — and a stomach with retained food can end a colonoscopy-day-adjacent EGD or obscure the view entirely; GI societies were co-authors of the modern guidance for exactly this reason, and their labs increasingly run explicit GLP-1 protocols. Emergency surgery removes the planning window: teams treat unplanned GLP-1 patients as full stomachs and manage accordingly, which is precisely why the medication list in your chart, wallet, or phone lock screen carries real safety weight. And obstetric anesthesia mostly shouldn't meet these drugs at all — labels advise discontinuation well before conception — but disclosure logic applies to anyone whose timeline blurred.

The meta-lesson this episode teaches

Step back and the anesthesia story is a well-functioning safety system in miniature: a new drug class scaled to millions, an edge case surfaced through case reports, imaging quantified it, first-draft guidance overcorrected toward caution, better evidence refined it toward individualized management — all within about two years, in public, with patients' role reducible to one word: disclosure. It's also a preview, because slowed emptying interacts with more than anesthesia (drug absorption timing is an active research thread), and because the next edge case for any blockbuster class will follow the same arc. A patient who tells every proceduralist about every medication — and asks "what's your protocol for this one?" — is not being difficult. They are the system working.

Questions people actually ask

Will they cancel my surgery just because I'm on a GLP-1? Under current multi-society guidance, routine cancellation is not the standard — continuation plus a clear-liquid window is, for most. Cancellations cluster around undisclosed use, day-of symptoms, or institutions still running older blanket-hold policies; the pre-visit question above is how you find out which world you're in before 6 a.m. on the day.

Should I secretly skip a dose "to be safe"? No — unilateral changes create the worst combination: destabilized therapy plus a care team planning around wrong assumptions. The safety comes from the team knowing exactly what you took and when; give them that and let them run their protocol.

Does this apply to light sedation, like a dental procedure? Deep sedation and general anesthesia carry the aspiration concern; minimal sedation and local anesthesia generally don't trigger these protocols. But "how deep is my sedation?" is a fair and answerable question for any proceduralist — ask it rather than classifying your own case.

I aspirated years ago for unrelated reasons. Extra risk now? A prior aspiration or significant reflux history belongs at the top of your disclosure, since it stacks with the medication effect in exactly the risk screens the guidance describes — you may be precisely the patient for whom an ultrasound check or modified plan earns its keep.

A script for the pre-op phone call

Because the entire modern protocol runs on one conversation, here is that conversation, ready to read. "I'm scheduled for [procedure] on [date]. I take [semaglutide/tirzepatide] at [dose], injected weekly on [day] — my last dose before the procedure would normally be [date]. It was last increased on [date]. I want to confirm three things: whether your protocol has me continue or hold the medication; what my liquid-diet and fasting windows are, exactly; and whether anything about my case — [mention any nausea, reflux, early fullness, prior aspiration, diabetes medications] — changes the plan. Can you note all of this in my chart?" Ninety seconds, and it converts you from the case that gets cancelled at 6:40 a.m. into the case the team pre-planned on Tuesday. If the answer you receive is a blanket "just stop it for a week" for a weekly drug, it's fair to ask one respectful follow-up — "is that under the current multi-society guidance, or your institution's own protocol?" — not to litigate, but because the answer tells you which framework you're inside and what else to expect on the day. Write down who you spoke with and when; pre-op instructions have a way of being re-asked at every subsequent checkpoint, and the name-and-date answer ends that loop instantly.

References

Primary sources for this article (verify against PubMed / FDA before external citation): ASA consensus guidance on GLP-1 agonists and procedures (June 2023); multi-society clinical practice guidance update (ASA/AGA/ASMBS and partners, 2024–2025); gastric ultrasound studies of retained contents in GLP-1 users (2023–2024); case literature on periprocedural regurgitation/aspiration. Verify current institutional protocols — they vary.